US-based Avanir Pharmaceuticals (AVNR) has entered into a settlement agreement with the US unit of Indian drugmaker Wockhardt to resolve pending patent litigation in response to Wockhardt's abbreviated new drug application (ANDA) seeking ...
Tags: Avanir Pharma, Medicine
Avanir Pharmaceuticals has settled pending patent litigation concerning Sandoz's abbreviated new drug application (ANDA) to market generic versions of Avanir's Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) capsules. Under the ...
Tags: Avanir Pharmaceuticals
Concert Pharmaceuticals has developed AVP-786 (CTP-786 or deuterated dextromethorphan) and reached a milestone under Avanir Pharmaceuticals collaboration. Avanir completed first of a two-stage pharmacokinetic study of AVP-786 in healthy ...
Tags: Concert Pharmaceuticals, Avanir Pharmaceuticals collaboration, AVP-786
The US Food and Drug Administration (FDA) has accepted Avanir Pharmaceuticals' investigational new drug (IND) application for the study of AVP-923, an investigational drug for the treatment of agitation in patients with Alzheimer's disease. ...
Tags: AVP-923, Alzheimer's disease, IND
The United States Patent and Trademark Office (USPTO) has issued notice of allowance for Avanir Pharmaceuticals' patent application covering Nuedexta. The patent application entitled, Pharmaceutical Compositions Comprising ...
Tags: USPTO, patent application, nuedexta, pseudobulbar affect